Metabolic profiles in adults with autism spectrum disorder and intellectual disabilities

European Psychiatry

Volumn 29, Issue 7, 2014, Pages 397-401

  Moses, L ^a,b   Katz, N ^c   Weizman, A ^c  

^a DIVISION FOR INTELLECTUAL AND DEVELOPMENTAL DISABILITIES   (Israel)

^b MACCABI HEALTHCARE SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autism; Cholesterol; Glucose; Intellectual disabilities; Metabolic profile

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOOD STABILIZER; OLANZAPINE; THYROTROPIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTISM; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE METABOLISM; HUMAN; INTELLECTUAL IMPAIRMENT; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC PARAMETERS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; CASE CONTROL STUDY; METABOLISM; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; RETROSPECTIVE STUDIES; THYROTROPIN; YOUNG ADULT;

EID: 84921522807     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2013.05.005     Document Type: Article

References (31)

1. Agargun M.Y., Ozer O.A., Kara H., Sekeroglu R., Selvi Y., Eryonucu B. Serum lipid levels in patients with dissociative disorder. Am J Psychiatry 2004, 161:2121-2123.
2. Apter A., Laufer N., Bar-Sever M., Har-Even D., Ofek H., Weizman A. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients. Biol Psychiatry 1999, 46:532-541.
3. Atasoy N., Erdogan A., Yalug I., Ozturk U., Konuk N., Atik L., et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1255-1260.
4. Buydens-Branch, Branchey M., Hudson J., Fergeson P. Low HDL cholesterol, aggression and altered central serotonergic activity. Psychiatry Res 2000, 93:93-102.
5. Cassidy F., Carroll B.J. Hypocholesterolemia during mixed manic episodes. Eur Arch Psychiatry Clin Neurosci 2002, 252:110-114.
6. Castilla-Puentes R. Effects of psychotropics on glycosylated hemoglobin (HbA1c) in a cohort of bipolar patients. Bipolar Disord 2007, 9:772-778.
7. Choong E., Bondolfi G., Etter M., Jermann F., Aubry J.M., Bartolomei J., et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012, 46:540-548.
8. Cohen S., Fitzgerald B., Okos A., Khan S., Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003, 64:60-62.
9. de Winter C.F., Bastiaanse L.P., Hilgenkamp T.I., Evenhuis H.M., Echteld M.A. Cardiovascular risk factors (diabetes, hypertension, hypercholesterolemia and metabolic syndrome) in older people with intellectual disability: results of the HA-ID study. Res Dev Disabil 2012, 33:1722-1731.
10. Duntas L.H. Thyroid disease lipids. Thyroid 2002, 12:287-293.
11. Dziobek I., Gold S.M., Wolf O.T., Convit A. Hypercholesterolemia in Asperger syndrome: independence from lifestyle, obsessive-compulsive behavior, and social anxiety. Psychiatry Res 2007, 149:321-324.
12. Gaulin B.D., Markowitz J.S., Caley C.F., Nesbitt L.A., Dufresne R.L. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999, 156:1270-1272.
13. Golier J.A., Marzuk P.M., Leon A.C., Weiner C., Tardiff K. Low serum cholesterol level and attempted suicide. Am J Psychiatry 1995, 152:419-423.
14. Kim Y.K., Myint A.M. Clinical application of low serum cholesterol as an indicator for suicide risk in major depression. J Affect Disord 2004, 81:161-166.
15. Kim E.K., Neggers Y.H., Shin C.S., Kim E., Kim E.M. Alterations in lipid profile of autistic boys: a case control study. Nutr Res 2010, 30:255-260.
16. Lin P.Y., Lin L.P., Lin J.D. Hypertension, hyperglycemia, and hyperlipemia among adolescents with intellectual disabilities. Res Dev Disabil 2010, 31:545-550.
17. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003, 160:290-296.
18. Lorenzo C., Hanley A.J., Rewers M.J., Haffner S.M. The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study. Diabetologia 2013, 56:746-757.
19. Malone R.P., Delaney M.A., Hyman S.B., Cater J.R. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 2007, 17:779-790.
20. Ming X., Stein T.P., Barnes V., Rhodes N., Guo L. Metabolic perturbance in autism spectrum disorders: a metabolomics study. J Proteome Res 2012, 11:5856-5862.
21. Murdoch J.C., Rodger J.C., Rao S.S., Fletcher C.D., Dunnigan M.G. Down's syndrome: an atheroma-free model?. Br Med J 1977, 2:226-228.
22. Nir I., Meir D., Zilber N., Knobler H., Hadjez J., Lerner Y. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995, 25:641-654.
23. Pueschel S.M., Craig W.Y., Haddow J.E. Lipids and lipoproteins in persons with Down's syndrome. J Intellect Disabil Res 1992, 36(Pt 4):365-369.
24. Raeder M.B., Ferno J., Vik-Mo A.O., Steen V.M. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?. Mol Cell Biochem 2006, 289:167-173.
25. Repo-Tiihonen E., Halonen P., Tiihonen J., Virkkunen M. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder. Eur Arch Psychiatry Clin Neurosci 2002, 252:8-11.
26. Salo M.K., Solakivi-Jaakkola T., Kivimaki T., Nikkari T. Plasma lipids and lipoproteins in Down's syndrome. Scand J Clin Lab Invest 1979, 39:485-490.
27. Sikora D.M., Pettit-Kekel K., Penfield J., Merkens L.S., Steiner R.D. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006, 140:1511-1518.
28. Steinert T., Woelfle M., Gebhardt R.P. No correlation of serum cholesterol levels with measures of violence in patients with schizophrenia and non-psychotic disorders. Eur Psychiatry 1999, 14:346-348.
29. Targher G., Montagnana M., Salvagno G., Moghetti P., Zoppini G., Muggeo M., et al. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clin Endocrinol (Oxf) 2008, 68:481-484.
30. Tierney E., Bukelis I., Thompson R.E., Ahmed K., Aneja A., Kratz L., et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2006, 141 B:666-668.
31. Tsiouris J.A., Kim S.Y., Brown W.T., Pettinger J., Cohen I.L. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord 2013, 43:719-731.